Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients

Cailleteau, Axel; Sargos, P.; Saad, Fred; Latorzeff, I.; Supiot, S.

doi:10.3389/fonc.2021.780507

Cited by 3 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The French randomized phase 3 CARLHA-2/GETUG-AFU 33 trial (NCT04181203) comparing prostate bed and pelvic RT with 6 months of ADT ± apalutamide for high-risk relapsing patients is currently recruiting. Other therapies targeting the Pi3K/Akt/mTOR pathway or glucose metabolism (such as metformin) are under investigation [ 54 ]. Finally, the use of therapeutic PSMA radiopharmaceuticals, such as Lu-PSMA, will also be of interest in this population with microscopic residual disease ( Table 4 ).…”

Section: Discussion and Perspectivesmentioning

confidence: 99%

Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives

Terlizzi

Limkin

Moukasse

et al. 2022

Cancers

View full text Add to dashboard Cite

Nearly one-third of the patients who undergo prostatectomy for prostate cancer have a biochemical recurrence (BCR) during follow-up. While several randomized trials have shown that adjuvant radiation therapy (aRT) improves biochemical control, this strategy has not been widely used because of the risk of toxicity and the fear of overtreating patients who would not have relapsed. In addition, the possibility of close PSA monitoring in the era of ultrasensitive assays enables to anticipate early salvage strategies (sRT). Three recent randomized trials and their meta-analysis have confirmed that aRT does not improve event-free survival compared to sRT, imposing the latter as the new standard of treatment. The addition of androgen deprivation therapy (ADT) to RT has been shown to improve biochemical control and metastasis-free survival, but the precise definition of to whom it should be proposed is still a matter of debate. The development of genomic tests or the use of artificial intelligence will allow more individualized treatment in the future. Therapeutic intensification with the combination of new-generation hormone therapy and RT is under study. Finally, the growing importance of metabolic imaging (PET/CT) due to its performance especially for low PSA levels will help in further personalizing management strategies.

show abstract

Section: Discussion and Perspectivesmentioning

confidence: 99%

Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives

Terlizzi

Limkin

Moukasse

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…DHT binds to ARs which then translocate from the cytoplasm to the nucleus, where they bind to the androgen response element (ARE) and initiate a transcription response. ARs regulate cell proliferation, apoptosis, migration, invasion and differentiation [8,45]. High AR expression in PC has been shown to be associated with lower recurrence-free survival and disease progression [9,46].…”

Section: Ar Signalling and Radiotherapymentioning

confidence: 99%

Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer

Saxby

Boussios

Mikropoulos

2022

IJMS

View full text Add to dashboard Cite

Stereotactic ablative body radiotherapy (SABR) is currently used as a salvage intervention for men with oligometastatic prostate cancer (PC), and increasingly so since the results of the Stereotactic Ablative Body Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers (SABR-COMET) trial reported a significant improvement in overall survival with SABR. The addition of androgen deprivation therapy (ADT) to localised prostate radiotherapy improves survival as it sensitises PC to radiotherapy-induced cell death. The importance of the androgen receptor (AR) gene pathway in the development of resistance to radiotherapy is well established. In this review paper, we will examine the data to determine how we can overcome the upregulation of the AR pathway and suggest a strategy for improving outcomes in men with oligometastatic hormone-sensitive PC.

show abstract

Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)

Ah-Thiane,

Sargos,

Chapet

et al. 2023

Cancer Treatment Reviews

View full text Add to dashboard Cite

Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients

Cited by 3 publications

References 60 publications

Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives

Adjuvant or Salvage Radiation Therapy for Prostate Cancer after Prostatectomy: Current Status, Controversies and Perspectives

Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer

Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)

Contact Info

Product

Resources

About